Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin for CDAD prophylaxis in HSCT
NCT01691248Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fidaxomicin in Clostridium difficile infection (CDI), sponsored by Merck & Co.. Started Oct 2012; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01691248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01691248.